| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 26.0 | 22.8 | 33.4 |
| Other income | 0.0 | 0.0 | 0.1 |
| Total income | 26.0 | 22.8 | 33.5 |
| Profit before exceptional items & tax | 2.4 | 3.2 | 3.9 |
| Profit before tax | 2.4 | 3.2 | 3.9 |
| Net profit | 2.0 | 3.0 | 3.7 |
| Operating margin | 9.2% | 14.0% | 11.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -45.90% |
|---|---|
| Net profit, quarter on quarter | -33.30% |
| Revenue, year on year | -22.20% |
NSE results filing, NSE: INDOUS. Figures extracted from the filing.
Indo US Bio-Tech Ltd: key numbers
- Share price
- ₹77.60
- Market cap
- ₹155.6 Cr
- Revenue (annual)
- ₹110.4 Cr
- Net profit (annual)
- ₹13.12 Cr
- P/E (TTM)
- 13.6×Sector 29.0×
- Promoter holding
- 68.29%+0.00% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indo US Bio-Tech Ltd
All →Indo US Bio-Tech Annual Report
Indo Us Bio-Tech Ltd submitted its Annual Report for FY 2025-2026. The 22nd Annual General Meeting is scheduled for September 30, 2026.
Indo US Bio-Tech Annual General Meeting
Indo Us Bio-Tech Limited has issued a notice for its 22nd Annual General Meeting, scheduled for September 30, 2026, to be conducted via video conferencing.
Indo US Bio-Tech Board Meeting Outcome
Indo Us Bio-Tech Ltd announced outcomes of its board meeting, including the date for its 22nd AGM and appointment of statutory auditors.
Indo US Bio-Tech Q1 FY27 Results: Net Profit ₹3 Cr, Down 36.2% YoY
Indo US Bio-Tech Ltd reported revenue from operations of ₹33 Cr (+7.1% YoY) and net profit of ₹3 Cr (-36.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹3 Cr · -36.2% YoY